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Abstract
Background: Maraviroc treatment for HIV-1 infected patients results in larger CD4
+ T cell rises than are attributable to its
antiviral activity alone. We investigated whether this is due to modulation of T cell activation and inflammation.
Methods and Findings: Thirty maraviroc-treated patients from the Maraviroc versus Efavirenz Regimens as Initial Therapy
(MERIT) study were randomly selected from among those who had CCR5-tropic (R5) HIV on screening and achieved
undetectable HIV RNA (,50 copies/mL) by Week 48. Efavirenz-treated controls were matched for baseline characteristics to
the maraviroc-treated patients selected for this substudy. Changes in immune activation and inflammation markers were
examined for associations with CD4
+ T cell changes. Maraviroc treatment tended to result in more rapid decreases in CD38
expression on CD4
+ T cells and in plasma D-dimer concentrations than did treatment with efavirenz. The proportion of
patients with high-sensitivity C-reactive protein .2 mg/mL increased from 45% to 66% in the efavirenz arm, but remained
constant in the maraviroc arm (P=0.033). Decreases in CD38 expression on CD8
+ T cells were correlated with CD4
+ T cell
rises for maraviroc treatment (r=20.4, P=0.048), but not for treatment with efavirenz.
Conclusions: Maraviroc-treated patients had earlier, modest decreases in certain markers of immune activation and
inflammation, although in this small study, many of the differences were not statistically significant. Levels of high-
sensitivity C-reactive protein remained constant in the maraviroc arm and increased in the efavirenz arm. Decreases in
immune activation correlated with increased CD4
+ T cell gains.
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Introduction
Chronic HIV infection is characterized by persistent immune
activation, as measured by CD38 expression on T cells [1–3]. This
immune activation has been associated with CD4
+ Tc e l ll o s sa n d
diseaseprogression [1–4].After adequate controlofHIV replication,
the level of immune activation does not return to the levels observed
in uninfected adults [5]. This residual heightened T cell surface
expression of CD38 has been associated with lower CD4
+ Tc e l l
gains following highly active antiretroviral therapy (HAART) [5].
Increased plasma levels of inflammatory markers have also been
found in patients with appropriately treated HIV disease [6].
Inflammation has been linked to morbidity and mortality in HIV
infection. In the Strategies for Management of Antiretroviral
Therapy (SMART) study, increased levels of the pro-inflammatory
cytokine interleukin 6 (IL-6) and of D-dimer, a marker of
fibrinolysis, predicted all-cause mortality in persons with treated
HIV infection, and impaired liver function among hepatitis co-
infected patients [7,8]. Levels of IL-6 and high-sensitivity C-
reactive protein (hsCRP) were also independent predictors of
cardiovascular events and AIDS-related opportunistic infections
[8–10]. In addition, studies in non-HIV-infected populations have
shown that there may be a clinical benefit associated with reducing
inflammation in persons with elevated levels of these markers: In
the Justification for the Use of Statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin (JUPITER), individu-
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treated with rosuvastatin had a significantly reduced incidence of
major cardiovascular events [11]. This suggests that HIV-infected
patients with elevated markers of inflammation and immune
activation may also benefit from reduction of inflammation.
In the phase 3 MERIT study comparing the CCR5 antagonist
maraviroc (MVC) to the non-nucleoside reverse transcriptase
inhibitor efavirenz (EFV), patients who received MVC had
significantly greater increases in blood CD4
+ T cells than those
who received EFV, although a numerically higher proportion of
EFV-treated patients achieved undetectable (,50 copies/mL) HIV
RNA [12]. To determine whether the greater CD4
+ T cell recovery
on MVC might be related to a differential effect on cellular
activation and inflammation, we assayed stored samples from a
subset of patients from each arm of MERIT for markers of cellular
activation and plasma inflammatory markers. When analyzing the
inflammatory marker hsCRP, we selected 2.0 mg/mL as a
threshold level based on results of the JUPITER study that
suggested a clinical benefit to reducing inflammation for individuals
with hsCRP .2.0 mg/mL.
Materials and Methods
As described elsewhere [12], MERIT evaluated the virologic
and immunologic effects of MVC versus EFV, both given with
zidovudine/lamivudine, in treatment-naive patients with CCR5-
tropic (R5) HIV infection. MERIT participants were asked to
consent to storing blood samples for future research, and only
samples from patients who consented were analyzed. The MERIT
study, including written informed consent for stored specimens,
was approved by the Institutional Review Boards (IRB) or
Independent Ethics Committees (IEC) of all participating sites.
The protocol for the MERIT study is available as Protocol S1.
Table S1 lists the 24 IRBs and IECs responsible for patients in the
analysis described here. The current sub-analysis enrolled 30
MVC-treated patients randomly selected from among those who
achieved and maintained HIV RNA ,50 copies/mL between
weeks 24 and 48, had available plasma at all time points when
markers were assayed (weeks 4, 8, 12, 24, and 48) and peripheral
blood mononuclear cell (PBMC) samples at weeks 24 and 48, had
no documented or reported infections for 2 weeks prior to each
time point, and no evidence of HCV infection (Figure 1). EFV-
treated controls were matched to cases for age, baseline CD4
+ cell
count, and baseline HIV RNA. Each patient sample was assigned
a numerical code, and the laboratory personnel performing all
assays were blinded to the treatment arm from which each sample
was collected.
Frozen PBMCs were thawed in batch and T cells were
identified by size, granularity, and by positive staining with
Peridinin-chlorophyll-protein Complex (PerCP)-labeled murine
monoclonal antibody to CD3 and either allophycocyanin (APC)-
labeled antibody to CD4, or fluorescein isothiocyanate (FITC)-
labeled antibody to CD8. Electronically gated CD4
+ or CD8
+ T
lymphocytes were then analyzed for expression of CD38 with a
phycoerythrin (PE)-labeled antibody. CD38 expression is reported
as antibodies bound per cell. Appropriately conjugated murine
monoclonal isotype control antibodies were used for gating. All
antibodies were purchased from BD Bioscience, San Diego, CA.
Cells were stained for 10 min at room temperature, washed in
phosphate buffered saline with 1% bovine serum albumin and
0.1% sodium azide, then fixed in 1% formaldehyde and analyzed
using a dual-laser flow cytometer (FACSCaliber; Becton Dick-
inson, San Jose, CA) and CellQuest software (BD Bioscience).
Plasma was prepared by centrifugation of whole blood collected
into EDTA-containing tubes at 1500–20006g for 10–15 minutes
and was stored at 280uC until analysis. Plasma samples were
thawed and analyzed in batch. Levels of D-dimers (Asserachrom
D-DI immunoassay, Diagnostica Stago, Asnie `res sur Seine,
France), tumor necrosis factor receptor I (TNFRI) (R&D Systems,
Minneapolis, MN), TNFRII (Biosource, Nivelles, Belgium),
Neopterin (Alpco Diagnostics, Salem, NH), IL-6 (R&D Systems),
and hsCRP (United Biotec Incorporated, Mountain View, CA),
were measured by ELISA.
Immune activation markers were assayed over time and changes
reported as median and interquartile range. Differences in percent
change from baseline to week 24 and 48 between the two arms were
analyzed using a Wilcoxon Rank Sum test. A Cochran-Mantel-
Haenszel test was used to compare the treatment arms with respect
to a number exceeding threshold at week 48 while adjusting for
baseline status. Changes from baseline to week 48 of each marker
were analyzed for association with change from baseline to week 48
in CD4
+ cell count using Pearson’s correlation. The statistical
analysis plan was developed and specified prior to any execution of
Table 1. Markers of immune activation and inflammation at baseline.
Immunologic marker EFV + ZDV/3TC (n=29) MVC + ZDV/3TC (n=28)
CD4
+ activation (CD38 antibodies/cell), median (IQR) 1397 (927, 1809) 1395 (1049, 2071)
Percentage of activated CD4
+ cells (% CD38
+), median (IQR) 76.8 (64.9, 84.9) 74.3 (65.7, 82.2)
CD8
+ activation (CD38 antibodies/cell), median (IQR) 1925 (1117, 3001) 1878 (1533, 3165)
Percentage of activated CD8
+ cells (% CD38
+), median (IQR) 81.4 (67.8, 89.4) 81.9 (78.3, 88.9)
D-dimer, ng/mL, median (IQR) 89.4 (61.1, 208.7) 115.5 (71.2, 275.7)
IL-6, pg/mL, median (IQR) 1.9 (0.8, 2.9) 1.7 (1.1, 2.5)
hsCRP, mg/mL, median (IQR) 1.6 (1.0, 4.2) 1.4 (0.9, 3.4)
Proportion with hsCRP .2 mg/mL 44.8 35.7
IQR, interquartile range (25
th–75
th percentile); MVC, maraviroc; EFV, efavirenz; ZDV/3TC, zidovudine/lamivudine.
doi:10.1371/journal.pone.0013188.t001
Figure 1. Patient flow chart: MERIT Immune Activation Sub-analysis. Notes under Figure 1: MVC, maraviroc; EFV, efavirenz; ZDV, zidovudine;
3TC, lamivudine.
doi:10.1371/journal.pone.0013188.g001
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in this exploratory, hypothesis-generating set of analyses.
Results
Thirty randomly selected patients who had received MVC were
matched to 30 patients who had been treated with EFV based on
age, baseline CD4
+ T cell count, and baseline HIV RNA levels.
All patients selected for this sub-study had reached undetectable
(,50 copies/mL) viral levels in plasma between weeks 24 and 48.
Complete data sets were available for 28 MVC-treated and 29
EFV-treated patients. Most patients were male (EFV 72%, MVC
82%) and the median age of each group was 36. At baseline, HIV
RNA levels were 4.9 log10 copies/mL and CD4
+ lymphocyte
counts were 274 cells/mL in both treatment groups. Baseline levels
of immune activation and inflammation markers were similar
across the two groups (Table 1).
At week 48, MVC-treated patients had a mean change in CD4
+
T cell count of +212 cells/mL compared to +191 cells/mL for the
EFV group. In order to determine whether the increased
restoration of CD4
+ T lymphocytes in the MVC treated group
was related to decreases in lymphocyte activation, surface
expression of CD38 on T cells was measured at baseline, 24 and
48 weeks. Among patients treated with MVC, there was an earlier
decrease in CD38 expression on CD4
+ T cells than was seen
among EFV-treated patients, although this difference was not
statistically significant. There was a 20.1% decrease in CD38 levels
(as measured by antibody binding) on CD4
+ cells at week 24 versus
a 0.29% increase in CD38 levels in the EFV arm (P=0.137;
Figure 2A). The decreases in CD38 levels on CD8
+ T cells were
almost identical in the two arms (data not shown).
Plasma levels of D-dimers also tended to fall more rapidly
among patients treated with MVC, although the difference
between the arms was not significant (P=0.177 at Week 24;
Figure 2B). Between baseline and week 48, the proportion of EFV-
treated patients with hsCRP .2 mg/mL increased (from 45% to
66%) while the proportion of MVC-treated patients with hsCRP
.2 mg/mL remained constant (36%) (Figure 2C; P=0.033).
Levels of plasma IL-6 fell more quickly in the EFV arm, but this
difference did not approach significance (P=0.817 at Week 24;
P=0.448 at Week 48). Declines in plasma levels of soluble
TNFRI, soluble TNFR II, and neopterin were similar for the
MVC-treated and EFV-treated groups (data not shown).
Among MVC-treated patients, decreases in CD38 expression
on CD8
+ T cells were significantly correlated with the rise in blood
CD4
+ T cells (r=20.4, P=0.048,Table 2). This correlation was
not observed among EFV-treated patients. When both treatment
arms were combined, significant correlations were observed
between gains in CD4
+ T cells and decreases in CD38 expression
on both CD4
+ and CD8
+ T cells (Table 2).
Discussion
Treatment with MVC has resulted in larger increases in CD4
+
T cell counts than can be attributed to its antiviral effects alone
[12,13], and the mechanism responsible has not been identified. In
the current sub-analysis, MVC-treated patients demonstrated a
larger mean increase in CD4
+ T cells than EFV-treated patients,
consistent with the results of the larger MERIT study [12]. The
increase in CD4
+ T cell numbers associated with CCR5 inhibition
could be a simple consequence of blocking the trafficking of
CCR5
+ T cells between circulation and peripheral tissues.
Alternatively, interference with signaling via CCR5 antagonism
might more rapidly attenuate the immune activation that has been
linked to impaired CD4
+ T cell restoration in HIV infection
Figure 2. Treatment effects on markers of immune activation
and inflammation. Among maraviroc (MVC)-treated patients, there was
an earlier decrease in CD38 expression on CD4
+T cells (A), and plasma levels
of D-dimers tended to decrease more rapidly (B). The proportion of efavirenz
(EFV)-treated patients with hsCRP .2 mg/mL increased while the proportion
of MVC-treated patients with hsCRP.2 mg/mL remained constant (C).
Vertical lines represent interquartile ranges (IQR; 25
th–75
th percentile).
doi:10.1371/journal.pone.0013188.g002
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and cellular activation to determine whether the CD4
+ T cell rises
associated with MVC administration were related to modulation
of immune activation. Compared to patients receiving EFV,
patients receiving MVC tended to have earlier decreases in CD38
expression on their CD4
+ T cells. Decreases in CD38 expression
on CD8
+ T cells correlated with increases in CD4
+ T cell counts in
the MVC arm, but not in the EFV arm. When both arms were
combined, however, decreases in CD38 expression on both CD4
+
and CD8
+ T cells were linked to the magnitude of CD4
+ T cell
restoration. When taken together, this small data set, while not
conclusive, provides a preliminary indication that the enhanced
CD4
+ T cell restoration seen in patients treated with MVC may be
related more to interfering with immune activation pathways than
with cellular redistribution.
Treatment with MVC has effects on activation and inflamma-
tion in HIV infection that can be differentiated from the effects of
another antiretroviral treatment regimen. D-dimer levels tended to
fall more rapidly in MVC-treated patients, while levels of IL-6
tended to drop slightly earlier in patients treated with EFV. Levels
of CRP remained stable in the MVC arm and tended to increase
in patients in the EFV arm. The inflammatory marker CRP, when
measured with high sensitivity assays, is a known predictor of
cardiovascular events in the general population [15,16], and
among treated HIV-infected patients, has been associated with
cardiovascular events [10,17] and opportunistic infections [9].
Levels of CRP were assessed using a threshold value of 2 mg/mL
based on previous research indicating that individuals with a value
exceeding this level may have an increased risk of cardiovascular
events [18,19] and may benefit from reduction of inflammation
(11). More broadly, indices of inflammation and coagulation are
linked to AIDS-defining and non-AIDS-defining events and
mortality [7,20]. In recent studies, levels of inflammatory markers
in HIV-infected persons have been associated with internal carotid
intima-media thickness, a surrogate marker for cardiovascular
disease [21,22], consistent with a growing appreciation in other
settings that chronic inflammation and its effects on coagulation
may be important drivers of cardiovascular risk [11,15,16,18,19].
Since viral replication drives immune activation, initiation of
therapy in either arm caused an early decrease in viral load
accompanied by a decline in inflammation. The early, modest
differential effect of MVC on several markers suggests an
additional direct effect of the drug on immune activation and
inflammation. In addition, CCR5 has been implicated as a
determinant of cardiovascular risk in murine atherosclerosis
models [23] and in patients undergoing hemodialysis [24].
Whether the changes induced by MVC will be associated with
fewer inflammation-associated events among patients receiving
HAART, such as immune reconstitution inflammatory syndrome
and cardiovascular disease, is being explored in controlled trials.
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